Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.
Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges
- Views Icon Views
- Share Icon Share
Rick F. J. Kwekkeboom, Zhiyong Lei, Pieter A. Doevendans, René J. P. Musters, Joost P. G. Sluijter; Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin Sci (Lond) 1 September 2014; 127 (6): 351–365. doi: https://doi.org/10.1042/CS20140005
Download citation file: